Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Christy J. Wilson
Sr. Director, Pharma and Biotech Segment
Connect with Christy J. Wilson on LinkedIn
Follow Christy J. Wilson on Twitter
About the author:
Christy brings more than 20 years of global life science and healthcare industry experience to her role as Senior Director, Segment Marketing for the biopharmaceutical industry segment at Elsevier. In this capacity she is focused on understanding biopharmaceutical R&D challenges and the implications for Elsevier in terms of market led growth opportunities that will improve productivity and success for industry executives and their teams. She also plays a key role in increasing Elsevier’s share-of-voice and market share through strategic go-to-market planning and execution.
Prior to joining Elsevier, Christy held senior marketing and business development roles in Wolters Kluwer’s Pharma Solutions Business Unit where she was responsible for product management and marketing of the Adis portfolio of drug focused journals and newsletters, pipeline and clinical trials intelligence tools, and pharmacovigilance solutions. During her Wolters Kluwer tenure, Christy also worked in the group’s Healthcare Analytics business, a business that provided powerful data, applications, analytics, and consulting to help companies gain deep insight into the pharmaceutical market.
Christy resides in the greater New York City area and holds an MBA in International Business from DePaul University (Chicago) and a BS in Marketing, from Miami University (Ohio).
Posts by Christy J. Wilson
Posted on August 14th, 2019 in Pharma R&D
Few substances on earth have been surrounded by more confusion than marijuana. Harmless plant or illicit drug? Medicinal or recreational? Legal or illegal (or partially legal)? And what should we make of all these things associated with marijuana, like hemp and CBD oil?(more…)
Posted on July 2nd, 2019 in Pharma R&D
Even the most reliable drugs don’t work exactly the same for everyone who takes them. The reason for this is an ongoing mystery, but a new study just published in Nature suggests that it may have a lot to do with the microbiome.(more…)
Posted on June 28th, 2019 in Pharma R&D
The life sciences, like many sectors, are putting a higher and higher premium on good data. In our digital world, access to reliable data is a necessity, whether it’s healthcare providers counting on data analytics to inform patient care or drug developers requiring insightful data to create effective new therapies.(more…)
Posted on May 1st, 2019 in Pharma R&D
Apple is a company that has long been thought of us an innovator that has brought consumers an array of enticing gadgets, from home computers to iPods to smartphones. This technology has been transformative for its users, but mostly it has been associated with work and play. Increasingly, though, Apple appears to be interested in getting involved in another critical part of our lives: our health.(more…)